No Data
No Data
GLP-1 Concerns Clobbered This Healthcare Stock. Now It's Time to Buy.
ResMed makes its bank from products that battle sleep apnea. When that business seemed threatened, investors fled. Now it looks like they were too hasty. By Jacob Sonenshine ResMed is the latest
Express News | Resmed Inc : BofA Global Research Raises Price Objective to $230 From $225
These Top ASX 200 Growth Shares Could Rise 20% to 45%
Fortunately for growth investors, there are a lot of quality options for them to choose from on the Australian share market.
Insider Sale: CFO Brett Sandercock Sells Shares of ResMed Inc (RMD)
Where to Invest $10,000 in ASX 200 Shares in July
If you are lucky enough to have $10,000 burning a hole in your pocket, it could be worth putting it to work in the share market.
Resmed Inc CDI Holdings See Monthly Dip
No Data
muhamad Hazairudin s : Muhammad Hazairudin Shadan
151685330 : buying the dip, can see gains in next 2 weeks into July.